君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01877 君实生物

交易中 07-22 09:43:20

20.060

+0.470

+2.40%

最高20.300	最低19.580	成交量56.08万
今开19.660	昨收19.590	日振幅3.68%
总市值206.02亿	流通市值52.16亿	总股本10.27亿
成交额1,124万	换手率0.22%	流通股本2.60亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":20.06,"timestamp":1784684600767,"preClose":19.59,"halted":0,"volume":560800,"delay":0,"changeRate":0.02399183256763649,"floatShares":260000000,"shares":1027000000,"eps":-0.87,"marketStatus":"交易中","change":0.47,"latestTime":"07-22 09:43:20","open":19.66,"high":20.3,"low":19.58,"amount":11238633,"amplitude":0.036753,"askPrice":20.08,"askSize":2800,"bidPrice":20.02,"bidSize":1200,"shortable":3,"etf":0,"ttmEps":-0.691,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1784692800000},"marketStatusCode":2,"adr":0,"listingDate":1545580800000,"exchange":"SEHK","adjPreClose":19.59,"openAndCloseTimeList":[[1784683800000,1784692800000],[1784696400000,1784707200000]],"volumeRatio":2.556681,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物-U","latestPrice":37.68,"timestamp":1784684598000,"preClose":36.63,"halted":0,"volume":4387600,"delay":0,"premium":"-54.02"}},"requestUrl":"/m/hq/s/01877","defaultTab":"news","newsList":[{"id":"1179836663","title":"君实生物（01877）特瑞普利单抗扩展II-III期可切除非小细胞肺癌围手术期适应症补充申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1179836663","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179836663?lang=zh_cn&edition=full","pubTime":"2026-07-21 21:45","pubTimestamp":1784641536,"startTime":"0","endTime":"0","summary":"2026年7月21日，君实生物公告称，公司已收到国家药品监督管理局签发的《受理通知书》，受理号为CYSB2600212、CYSB2600213。此次补充申请拟将特瑞普利单抗联合含铂化疗的围手术期治疗适应症，由“可切除IIIA-IIIB期非小细胞肺癌成人患者”扩展至“可切除II-III期NSCLC成人患者”。肺癌是全球发病率与死亡率最高的恶性肿瘤。该随机、双盲、安慰剂对照III期临床试验共纳入501例II-III期可切除NSCLC患者。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653720822","title":"君实生物(01877.HK)：特瑞普利单抗联合化疗用于可切除 II-III 期非小细胞肺癌患者围手术期治疗的补充申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2653720822","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653720822?lang=zh_cn&edition=full","pubTime":"2026-07-21 21:27","pubTimestamp":1784640435,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1515","01877","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154874890","title":"君实生物特瑞普利单抗围手术期新适应症扩展申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1154874890","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154874890?lang=zh_cn&edition=full","pubTime":"2026-07-21 21:25","pubTimestamp":1784640356,"startTime":"0","endTime":"0","summary":"2026年7月22日，上海君实生物医药科技股份有限公司公告称，已收到国家药品监督管理局签发的《受理通知书》，其特瑞普利单抗注射液联合含铂化疗围手术期治疗、继之单药辅助治疗，用于可切除II-III期非小细胞肺癌成人患者的补充申请获得受理，受理号为CYSB2600212、CYSB2600213。此次申请将原已获批的“可切除IIIA-IIIB期NSCLC”适应症扩展至“可切除II-III期NSCLC”。特瑞普利单抗是中国首个获批上市的国产PD-1单抗。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653208394","title":"中欧基金葛兰二季报出炉：君实生物首进持仓前十，科伦药业获大举增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2653208394","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653208394?lang=zh_cn&edition=full","pubTime":"2026-07-21 20:28","pubTimestamp":1784636880,"startTime":"0","endTime":"0","summary":"2026年二季度期间，中欧基金投资总监葛兰旗下两只医药主题基金均逆势跑赢基准。澎湃新闻记者 丁欣晴\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-21/doc-iniiqquw9179532.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-07-21/doc-iniiqquw9179532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1064130708.USD","LU1934453819.USD","LU2148510915.USD","002422","LU1979443071.USD","01877","BK1515","LU1064131003.USD","BK0239","BK1161","BK1583","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653272674","title":"君实生物：特瑞普利单抗新适应症补充申请获受理 拓展至II-III期可切除非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2653272674","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653272674?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:42","pubTimestamp":1784634120,"startTime":"0","endTime":"0","summary":"7月21日，君实生物（688180/01877）发布公告，公司收到国家药品监督管理局核准签发的《受理通知书》，特瑞普利单抗联合含铂化疗围手术期治疗可切除II-III期非小细胞肺癌的补充申请获得受理。本次申请的适应症由可切除IIIA-IIIB期非小细胞肺癌扩展为可切除II-III期非小细胞肺癌。由于药品研发周期长，审批环节多，本次补充申请能否获得批准存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607213815805376.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["III","BK1583","BK1515","BK1161","01877","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653733442","title":"葛兰旗下中欧医疗健康混合二季报：君实生物(688180.SH)新进十大重仓 创新药及产业链仍是布局主要方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2653733442","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653733442?lang=zh_cn&edition=full","pubTime":"2026-07-21 17:16","pubTimestamp":1784625396,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月21日，中欧基金披露葛兰和赵磊共同管理的中欧医疗健康混合型证券投资基金2026年第2季度报告。此外，君实生物新进持仓前十，信立泰跌出十大重仓。葛兰在季报中指出，2026年第二季度，市场风格分化显著，医药生物板块经历大幅震荡，整体走势弱于大盘。葛兰表示，第三季度创新药及产业链仍是布局的主要方向。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK4585","BK4581","XLV","688180","BK1515","LNGR","MEDX","BK4588","LABU","159760","IXJ","01877","VHT","BK4550","159992","XBI","BK1574","BK1161","BK0239","IBBQ","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162098983","title":"港股直击 | 生物医药股板块走强，荣昌生物、药明合联、康诺亚涨近8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162098983","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162098983?lang=zh_cn&edition=full","pubTime":"2026-07-20 11:22","pubTimestamp":1784517729,"startTime":"0","endTime":"0","summary":"7月20日，生物医药股板块走强，荣昌生物、药明合联、康诺亚涨近8%，君实生物涨近7%，康方生物涨近6%，药明生物涨近5%。消息面上，创新药板块近期迎来多重催化。一方面，政策端持续释放支持信号，国务院发布《国民健康“十五五”规划》，提出加强创新药和医疗器械全链条支持，优化创新药及临床急需药品审评审批机制，进一步完善创新药发展环境。另一方面，国产创新药商业化和海外授权进展持续受到关注，工信部数据显示，今年上半年共有38款创新药获批上市，其中国产创新药占比超过80%。随着下半年全球医学会议密集召开，包括WCLC、ESMO、ASH等重要学术会议，部分创新药企业核心管线的临床数据将陆续披露，市场关注重点重新回到研发进展和商业化兑现能力。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","01877","09995","02162","02269","02513","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652164405","title":"君实生物跌10.09%，太平洋三个月前给出“买入”评级，目标价53.12元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652164405","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652164405?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:23","pubTimestamp":1784276609,"startTime":"0","endTime":"0","summary":"今日君实生物（688180）跌10.09%，收盘报35.1元。2026年4月17日，太平洋研究员周豫,戎晓婕发布了对君实生物的研报《拓益保持高速增长，关注AACR大会JS207和JS212数据读出》，该研报对君实生物给出“买入”评级，认为其目标价为53.12元，研报发布时股价为44.38元，预期涨幅为19.69%。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为64.51%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中邮证券的盛丽华。君实生物（688180）个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700029727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","601099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651585714","title":"君实生物：熊俊增持3,259,495股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651585714","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651585714?lang=zh_cn&edition=full","pubTime":"2026-07-15 15:37","pubTimestamp":1784101031,"startTime":"0","endTime":"0","summary":"证券之星消息，君实生物(688180)07月15日在投资者关系平台上答复投资者关心的问题。投资者提问：市场丧失理性，建议公司进行回购或高管进行增持以提振二级市场价格，保护中小投资者。谢谢！君实生物回复：尊敬的投资人，您好！感谢您的宝贵建议。2025年11月至2026年3月期间，公司控股股东、实际控制人之一兼董事长熊俊先生已增持公司A股和H股股份合计3,259,495股，占公司总股本的0.32%，累计成交总额为人民币100,638,052.19元。后续如有回购或增持相关事项，公司将严格按照相关规定及时履行信息披露义务。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500025279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","01877","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651991128","title":"【券商聚焦】中信证券：新基药目录有望加速创新药基层落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2651991128","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651991128?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:57","pubTimestamp":1783990650,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，《2026年版国家基本药物目录》于7月9日正式发布，将于9月1日起实施。该机构认为，本次新版基药目录新增药物均已属于医保药品，随着基药与医保的深度协同联动，有望极大加速创新药的基层落地，医保控费与创新回报形成良性循环。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985769","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274720.SGD","LU2488822045.USD","LU0051755006.USD","IBBQ","06185","02142","01801","LU1960683339.HKD","09688","600030","LU0979878070.USD","09995","LU1226287792.SGD","LU2328871848.SGD","BK1500","01177","LU0359201612.USD","02269","LU0823426480.USD","LU0572944931.SGD","01877","LU0417516902.SGD","02616","LU0043850808.USD","KURE","LU0588546209.SGD","LU1152091168.USD","LU1242518931.SGD","LU1328277881.USD","LU0314109678.HKD","LU1997244956.HKD","06160","LU2039709279.SGD","LU0327786744.USD","BK1610","MEDX","LU1961090484.USD","BK1161","LU1226288253.USD","SG9999002463.SGD","IE00BPRC5H50.USD","09926","159992","06978","01093","HK0000165453.HKD","KCE","IE0008368742.USD","LU0405327494.USD","06030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651568164","title":"【券商聚焦】中信建投：创新药企仍是高增长主线、BD交易持续催化业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2651568164","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651568164?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:53","pubTimestamp":1783903985,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，1）制药产业链：创新药企仍是高增长主线，BD交易持续催化业绩。BD授权收入成为多家公司中期业绩关键变量。上游供应链受益于国产替代及下游需求恢复，Q2增速普遍提升，利润端弹性显著。建议关注Q2高增长公司的配置机会。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985645","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242644610.SGD","LU2097828631.EUR","KURE","02616","06185","LU0359201612.USD","LU1961090484.USD","KCE","LU1993786604.SGD","LU0516422366.SGD","LU2488822045.USD","IE00B5MMRT66.SGD","LU0501845795.SGD","LU1807302812.USD","LU0456846285.SGD","09688","601066","LU0348825331.USD","01801","MEDX","LU0051755006.USD","09995","02269","02142","IE00B0JY6N72.USD","LU1960683339.HKD","LU0067412154.USD","LU1969619763.USD","IE0008369823.USD","IBBQ","LU2097828474.EUR","BK1161","LU0348735423.USD","LU1688375341.USD","06160","LU0455707207.USD","BD","LU0348784397.USD","BK1515","IE0008368742.USD","LU1226288170.HKD","01177","01093","LU0359202008.SGD","BK1588","159992","09926","LU1813983027.USD","06978","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650154819","title":"每周股票复盘：君实生物（688180）拟回购不超10%H股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2650154819","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650154819?lang=zh_cn&edition=full","pubTime":"2026-07-12 01:58","pubTimestamp":1783792690,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，君实生物报收于37.6元，较上周的37.99元下跌1.03%。本周关注点公司公告汇总：君实生物拟回购不超过已发行H股总数10%的股份。君实生物2026年第一次临时股东会会议资料上海君实生物医药科技股份有限公司提请2026年第一次临时股东会审议《关于回购公司H股股份一般性授权的议案》。授权期限至2026年年度股东会结束或股东会决议撤回授权之日止。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","01877","BK1583","BK1515","688180","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650827906","title":"港股异动 | 君实生物(01877)涨超5% 宣布君迈康®纳入2026年版国家基本药物目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2650827906","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650827906?lang=zh_cn&edition=full","pubTime":"2026-07-10 10:23","pubTimestamp":1783650202,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，君实生物涨超5%，截至发稿，涨5.44%，报19.53港元，成交额4426.19万港元。消息面上，据君实生物官微消息，7月9日，公司宣布，君迈康被纳入新版《国家基本药物目录》，持续惠及类风湿关节炎、强直性脊柱炎、银屑病等自身免疫性慢病患者。君迈康由君实生物和迈威生物共同开发，2022年首次在国内获批上市，已纳入国家医保乙类目录。该产品合作已覆盖17个国家，并在7个国家递交上市申请，2025年已于印度尼西亚获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465704.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","VXUS","BK4585","01877","BK1583","KCAI","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649991088","title":"君实生物（688180）披露关于回购公司H股股份一般性授权的议案，7月8日股价下跌2.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649991088","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649991088?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:16","pubTimestamp":1783520182,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘，君实生物报收于35.9元，较前一交易日下跌2.71%，最新总市值为368.58亿元。该股当日开盘36.5元，最高37.25元，最低35.8元，成交额达6.99亿元，换手率为2.51%。近日，君实生物发布《关于回购公司H股股份一般性授权的议案》相关公告。授权事项包括制定具体回购方案、开立境外账户、办理外汇登记、履行监管备案程序、注销股份或作为库存股持有等。授权期限至2026年年度股东会结束或股东会决议撤回授权之日止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800042646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688180","01877","BK1515","BK0239","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197441399","title":"君实生物(01877)将于2026年7月27日召开临时股东会审议H股回购授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1197441399","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197441399?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:11","pubTimestamp":1783519905,"startTime":"0","endTime":"0","summary":"上海君实生物医药科技股份有限公司7月8日公告，公司拟于2026年7月27日14时50分在中国上海市浦东新区平家桥路100弄6号7幢15层召开2026年第一次临时股东大会。会议将审议一项特别决议案：授权董事会就公司H股股份进行回购的一般性授权。为确定有权出席并投票的股东名单，公司将于2026年7月22日至2026年7月27日暂停办理H股股份过户登记。君实生物提醒股东及委任代表出席会议时须出示身份证明文件，相关交通及食宿费用自理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109547614","title":"君实生物拟回购最多10%已发行H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1109547614","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109547614?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:05","pubTimestamp":1783519557,"startTime":"0","endTime":"0","summary":"君实生物医药科技股份有限公司公告称，董事会将寻求一般性授权，以通过香港联合交易所有限公司（联交所）回购不超过该公司已发行H股总数10%的股份，最高规模达约2602.96万股。根据公告，截至最新实际可行日期，君实生物合计拥有约10.27亿股已发行股份，其中包含约2.60亿股H股。公告称，如进行回购，回购价格不得等于或高于联交所前五个交易日平均收市价的105%。董事会认为，本次回购安排符合公司与全体股东的整体利益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"君实生物拟回购最多10%已发行H股","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164744147","title":"君实生物（01877）拟7月22日至27日暂停H股过户登记 以确定临时股东会出席资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1164744147","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164744147?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:51","pubTimestamp":1783515103,"startTime":"0","endTime":"0","summary":"上海君实生物医药科技股份有限公司（01877）7月8日公告称，公司将于2026年7月22日（星期三）至2026年7月27日（星期一）（包括首尾两日）暂停办理H股股份过户登记手续。此次暂停旨在确定有权出席并在2026年7月27日（星期一）召开的2026年第一次临时股东会投票的H股持有人名册。\n公司提示，所有有关H股过户文件及相关股票、过户表格需在2026年7月21日（星期二）16时30分前提交至公司H股股份过户登记处卓佳证券登记有限公司（地址：香港夏悫道16号远东金融中心17楼）。\n根据公告，临时股东会记录日期确定为2026年7月27日（星期一）。公告由公司董事会主席熊俊签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158343099","title":"君实生物（01877）拟于7月27日召开股东会　表决10% H股回购授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1158343099","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158343099?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:45","pubTimestamp":1783514749,"startTime":"0","endTime":"0","summary":"上海君实生物医药科技股份有限公司7月9日公告，将于2026年7月27日14时50分在上海市浦东新区平家桥路100弄6号7幢15层召开2026年第一次临时股东大会，并同步开放上海证券交易所网络投票系统。会议唯一议案为《关于回购公司H股股份一般性授权的议案》。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649004626","title":"甘李药业涨停，君实生物港股盘中涨超8%，创新药板块为何活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2649004626","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649004626?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:36","pubTimestamp":1783337760,"startTime":"0","endTime":"0","summary":"7月6日，A股和H股创新药板块表现活跃，走势向好。A股方面，首药控股（688197.SH）、三元基因（920344）、诚达药业（301201.SZ）等收涨10%以上，甘李药业（603087.SH）10%涨停，罗欣药业（002793.SZ）、热景生物（688068.SH）、艾迪药业（688488、SH）、华海药业（600521.SH）等涨超9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607063795316738.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607063795316738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["603087","06978","BK1515","BK1574","BK0239","01877","BK1161","IBBQ","MEDX","BK4588","KCAI","BK1583","159992","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649946426","title":"每周股票复盘：君实生物（688180）授权复星万邦获2.15亿首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2649946426","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649946426?lang=zh_cn&edition=full","pubTime":"2026-07-05 02:12","pubTimestamp":1783188734,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，君实生物报收于37.99元，较上周的29.68元上涨28.0%。本周关注点来自公司公告汇总：君实生物授权复星万邦开发抗IL-17A单抗，获2.15亿元首付款。公司可获得2.15亿元首付款，最高11.25亿元里程碑付款，以及大中华地区净销售额双位数百分比的分级销售提成。股本总额维持为人民币1,026,689,871元。H股和A股股票期权激励计划已于2025年9月29日获批准采纳，当月无新增行权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","01877","BK1161","BK1515","688180","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://junshipharma.com","stockEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":0.196},{"period":"3month","weight":-0.2984},{"period":"6month","weight":-0.1355},{"period":"1year","weight":-0.2195},{"period":"ytd","weight":-0.082}],"compareEarnings":[{"period":"1week","weight":0.0325},{"period":"1month","weight":0.0505},{"period":"3month","weight":-0.0394},{"period":"6month","weight":-0.0562},{"period":"1year","weight":0.0055},{"period":"ytd","weight":-0.0194}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海君实生物医药科技股份有限公司是一家主要从事创新驱动生物制药业务的中国公司。该公司主营业务为创新药物的发现、临床研究和开发。该公司的主要产品包括特立普珠单抗注射液、依替维单抗、阿达木单抗注射液等用于治疗恶性肿瘤、自身免疫系统疾病、慢性代谢疾病、神经系统疾病和感染性疾病的药物。该公司还从事重组人源化抗PCSK9单克隆抗体注射液等药物的临床研发。该公司主要为国内外市场提供产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.098181},{"month":2,"riseRate":0.75,"avgChangeRate":0.062525},{"month":3,"riseRate":0.75,"avgChangeRate":0.059343},{"month":4,"riseRate":0.875,"avgChangeRate":0.105939},{"month":5,"riseRate":0.375,"avgChangeRate":-0.021039},{"month":6,"riseRate":0.375,"avgChangeRate":-0.04216},{"month":7,"riseRate":0.625,"avgChangeRate":0.009308},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.040587},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.026161},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.004518},{"month":11,"riseRate":0.571429,"avgChangeRate":0.043753},{"month":12,"riseRate":0.571429,"avgChangeRate":0.085319}],"exchange":"SEHK","name":"君实生物","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,01877,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}